| Citation: |
LIU Chen, YE Jianwen, WANG Xuemei, LI Hua. Predictive value of serum microRNA-506 and microRNA-934 levels in postoperative survival outcome of patients with pancreatic cancer[J]. Journal of Clinical Medicine in Practice, 2024, 28(5): 40-43. DOI: 10.7619/jcmp.20233000
|
To investigate the predictive value of serum microRNA-506 (miR-506) and microRNA-934 (miR-934) expression levels in postoperative survival outcomes of patients with pancreatic cancer.
A total of 115 patients with pancreatic cancer who received surgical treatment were selected as the study group, and were divided into survival group (n=18) and death group (n=97) according to the follow-up results. Fifty patients with benign pancreatic lesions in the same period were selected as control group; fifty healthy volunteers were selected as the healthy group. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the relative expression levels of miR-506 and miR-934 in serum of each group. Multivariate Logistic regression analysis was used to analyze the influencing factors of postoperative survival outcomes in patients with pancreatic cancer. The predictive value of serum miR-506 and miR-934 in postoperative survival outcome of pancreatic cancer patients was analyzed by receiver operating characteristic (ROC) curve.
The expression level of serum miR-506 in the study group was significantly lower than that in the control group (P < 0.05). The expression level of serum miR-934 in the study group was significantly higher than that in the control group and healthy group (P < 0.05). The expression level of serum miR-506 in the survival group was significantly higher than that in the death group, and the expression level of serum miR-934 was significantly lower than that in the death group (P < 0.05). The miR-506, miR-934, TNM stage and lymph node metastasis were independent factors influencing postoperative survival of pancreatic cancer patients (P < 0.05).
The expression of miR-506 is low in the serum of patients who died after pancreatic cancer surgery, and the expression of miR-934 is high in the serum of patients who died after pancreatic cancer surgery. The value of miR-506 and miR-934 in predicting postoperative survival outcome of pancreatic cancer patients is high.
| [1] |
MIZRAHI J D, SURANA R, VALLE J W, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. doi: 10.1016/S0140-6736(20)30974-0
|
| [2] |
吴白骏, 胡朝全. 胰腺癌免疫治疗的现状与进展[J]. 实用临床医药杂志, 2022, 26(13): 134-138, 144. doi: 10.7619/jcmp.20220016
|
| [3] |
郭继红, 朱宁, 葛洋, 等. 晚期胰腺癌患者的临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(3): 501-506. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYD202303022.htm
|
| [4] |
王小蕊, 董非斐, 何碧凝, 等. MiR-506-3p通过靶向IQGAP1基因抑制甲状腺癌细胞增殖、迁移和侵袭的体外研究[J]. 中国老年学杂志, 2021, 41(18): 4073-4078. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ202118056.htm
|
| [5] |
钟有清, 周向东, 李琪, 等. MiR-506通过调控MCL-1抑制耐阿立替尼非小细胞肺癌A549细胞上皮间质转化的作用机制[J]. 现代肿瘤医学, 2021, 29(2): 190-195. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202102003.htm
|
| [6] |
LU Y X, HU X X, YANG X Y. MiR-934 promotes breast cancer metastasis by regulation of PTEN and epithelial-mesenchymal transition[J]. Tissue Cell, 2021, 71: 101581. doi: 10.1016/j.tice.2021.101581
|
| [7] |
HU Y, ZHANG Q, CUI J, et al. Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13): 5595-5602.
|
| [8] |
JIN Y B, WENG Y C, WANG Y, et al. MiR-934 as a prognostic marker facilitates cell proliferation and migration of pancreatic tumor by targeting PROX1[J]. Onco Targets Ther, 2020, 13: 3389-3399. doi: 10.2147/OTT.S249662
|
| [9] |
杨尹默, 刘光年, 田孝东. 胰腺癌外科治疗若干热点问题[J]. 中国实用外科杂志, 2023, 43(7): 729-734. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202307002.htm
|
| [10] |
韩伟光, 王青. 胰腺癌不同分期的差异基因筛选及关键蛋白调控基因的预后分析[J]. 空军军医大学学报, 2023, 44(5): 432-437. https://www.cnki.com.cn/Article/CJFDTOTAL-DSJY202305010.htm
|
| [11] |
贺龙梅, 马燕粉, 王晓倩, 等. CA199、IL-10、CHI3L1联合检测在胰腺癌诊断中的价值[J]. 检验医学与临床, 2021, 18(24): 3521-3524. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYL202124005.htm
|
| [12] |
ZHAO Z Y, LIU W. Pancreatic cancer: a review of risk factors, diagnosis, and treatment[J]. Technol Cancer Res Treat, 2020, 19: 1533033820962117.
|
| [13] |
GOTO T, FUJIYA M, KONISHI H, et al. An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker[J]. BMC Cancer, 2018, 18(1): 116. doi: 10.1186/s12885-018-4006-5
|
| [14] |
李秀明, 刘璐, 万琼, 等. 新辅助治疗后血清miR-448和miR-143水平对胰腺癌患者术后生存和预后的影响[J]. 实用癌症杂志, 2022, 37(8): 1331-1334. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202208030.htm
|
| [15] |
胡新祥, 汪茂超, 李炜, 等. 结肠癌患者血清miR-506、SPON1 mRNA表达水平与5年预后的关系[J]. 中国卫生检验杂志, 2023, 33(8): 945-949. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ202308013.htm
|
| [16] |
林燕玲, 王瑛, 张敏, 等. 上皮性卵巢癌组织中miR-506-3p及miR-532-5p的表达与临床病理特征及预后的相关研究[J]. 现代检验医学杂志, 2022, 37(3): 83-86. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYN202203017.htm
|
| [17] |
詹学斌, 岳颖, 马剑锋. 原发性肝癌患者血清miR-934和miR-498水平变化及其诊断价值和对预后的影响[J]. 实用癌症杂志, 2022, 37(9): 1440-1443. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202209011.htm
|
| 1. |
谷胜男，史梦迪，杨阳，刘璐佳，王有鹏. 分消走泄法治疗儿童特应性皮炎机制研究进展. 陕西中医. 2024(05): 715-718 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: